Table 1 Patient sociodemographic and clinical characteristics

Age, years, mean (SD)^a

41.3 (16.3)

43.1 (15.6)

41.8 (15.8)

Sex, n (%)^a

 Female

11 (55)

5 (63)

16 (57)

Race, n (%)^a

 White/Caucasian/European

12 (60)

8 (100)

20 (71)

 Mixed race

3 (15)

0

3 (11)

 African American/African Heritage

2 (10)

0

2 (7)

 Mexican

2 (10)

0

2 (7)

 Native Hawaiian or other Pacific islander

1 (5)

0

1 (4)

Clinician-reported asthma severity level, n (%)

 Mild

2 (10)

0

2 (7)

 Moderate

10 (50)

6 (75)

16 (57)

 Severe

8 (40)

2 (25)

10 (36)

Age of asthma diagnosis, years, n (%)

 0–17

5 (25)

2 (25)

7 (25)

 18–25

9 (45)

2 (25)

11 (39)

 26–35

3 (15)

3 (38)

6 (21)

 36– < 40

3 (15)

1 (13)

4 (14)

Asthma Control Test (ACT)^a, at screening

 Mean (SD)

14.75 (3.6)

12.50 (2.9)

14.11 (3.5)

 Well controlled (≥ 20), n (%)

5 (25)

0

5 (18)

 Not well-controlled (16–19), n (%)

9 (45)

0

9 (32)

 Very poorly controlled (≤ 15), n (%)

6 (30)

8 (100)

14 (50)

Medication step needed to maintain control, n (%)^a

 GINA Step 2

8 (40)

0

8 (29)

 GINA Step 3

3 (15)

2 (25)

5 (18)

 GINA Step 4

9 (45)

5 (63)

14 (50)

 GINA Step 5

0

1 (13)

1 (4)

Comorbidities, n (%)

 Allergies

5 (25)

7 (88)

12 (43)

 Allergic rhinitis

5 (25)

3 (38)

8 (39)

 Cardiac disorders

2 (10)

0

2 (7)

 Blood and lymphatic system disorders

1 (5)

0

1 (4)

 Osteoarthritis—‘back issues’

1 (5)

0

1 (4)

 Metabolism and nutrition disorders

1 (5)

0

1 (4)

 Respiratory, thoracic, and mediastinal disorders

0

1 (13)

1 (4)

 Skin/subcutaneous tissue disorders

0

1 (13)

1 (4)

 Psychiatric disorders

0

1 (13)

1 (4)

Maintenance medication, n (%)

 Leukotriene receptor antagonist

8 (40)

4 (50)

12 (43)

 ICS/LABA (single inhaler)

12 (60)

5 (63)

17 (61)

 ICS/LABA/LAMA (single inhaler)

0

3 (38)

3 (11)

 ICS

7 (35)

0

7 (25)

 LABA

0

1 (13)

1 (4)

 Monoclonal antibody

3 (15)

6 (75)

9 (32)

 LAMA/LABA

2 (10)

0

2 (7)

 LAMA

0

3 (38)

3 (11)

 SABA

1 (5)

1 (13)

2 (7)